This inventor holds 2 USPTO granted patents. Top assignee: Kyorin Pharmaceutical Co., Ltd.. Active years: 1994-1998.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Nogi, JP (1994)
- Nogi-machi, JP (1998)
Company Filing History:
Years Active: 1994-1998
Title: Atsuhiro Yamanishi: Innovator in Therapeutic Drug Development
Introduction
Atsuhiro Yamanishi is a notable inventor based in Nogi, Japan. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of therapeutic drugs. His innovative work has led to the filing of multiple patents, showcasing his expertise and dedication to advancing medical treatments.
Latest Patents
Yamanishi holds 2 patents that focus on the development of imidazolidinone derivatives and carbamic acid derivatives. His latest patents include formulations for anti-dementia medicaments that comprise carbamic acid derivatives or their pharmaceutically acceptable acid addition salts. These compounds are designed to exhibit anti-amnesic activity, providing potential therapeutic benefits for patients suffering from dementia. The carbamic acid derivatives are represented by a specific general formula, which includes various substituents and functional groups that enhance their efficacy.
Career Highlights
Yamanishi is currently associated with Kyorin Pharmaceutical Co., Ltd., where he continues to engage in innovative research and development. His work at Kyorin has positioned him as a key player in the pharmaceutical industry, contributing to the advancement of new therapeutic options for various medical conditions.
Collaborations
Throughout his career, Yamanishi has collaborated with esteemed colleagues, including Yasuo Takano and Masanori Takadoi. These collaborations have fostered a productive environment for innovation and have led to the successful development of new pharmaceutical products.
Conclusion
Atsuhiro Yamanishi's contributions to the field of therapeutic drug development are commendable. His innovative patents and collaborations reflect his commitment to improving healthcare through scientific advancements. His work continues to inspire future innovations in the pharmaceutical industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
